LRFN1: A Potential Drug Target and Biomarker for Synaptic Adhesion-Like Molecule 2

Target Name: LRFN1

NCBI ID: G57622

LRFN1

LRFN1: A Potential Drug Target and Biomarker for Synaptic Adhesion-Like Molecule 2

Synaptic adhesion-like molecule 2 (SLAM-2) is a protein that plays a crucial role in the formation and maintenance of synaptic plasticity, which is the ability of the nervous system to change and adapt over time. SLAM-2 is a transmembrane protein that is expressed in all brain regions and is involved in various signaling pathways, including the development and maintenance of neural circuits.

Recent studies have identified SLAM-2 as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. SLAM-2 has also been shown to be involved in the development of glaucoma, a leading cause of blindness.

LRFN1 is a gene that encodes a protein similar to SLAM-2. It has been shown to be highly expressed in the brain and is involved in various neural processes, including the development and maintenance of synaptic plasticity. LRFN1 has also been implicated in the development and progression of various neurological and psychiatric disorders.

The ability of LRFN1 to interact with SLAM-2 and other synaptic proteins suggests that it may be a useful biomarker or drug target for SLAM-2-related disorders.

LRFN1 has been shown to interact with various SLAM-2-related proteins, including synaptonemal complex protein (SNX), which is a protein that is involved in the formation of the synaptic plasma membrane. SNX has also been shown to interact with SLAM-2 and is involved in the formation ofSLAM-2-containing synapses.

LRFN1 has also been shown to interact with the protein PDZ1, which is involved in the formation of synaptic adhesion. PDZ1 has been shown to interact with SLAM-2 and is involved in the formation of SLAM-2-containing synapses.

The ability of LRFN1 to interact with these SLAM-2-related proteins suggests that it may be a useful biomarker or drug target for SLAM-2-related disorders.

LRFN1 has also been shown to play a role in the development and maintenance of synaptic plasticity. as well as the regulation of neurotransmitter release.

LRFN1 has also been shown to be involved in the regulation of synapse formation and apoptosis, which is the formation and elimination of synaptic connections. Apoptosis is a form of neuronal death that occurs in neuronal damage and neurodegenerative diseases. plays an important role. LRFN1 has been shown to be involved in the regulation of synaptic terminal maturation, which is the process by which synaptic connections are established and optimized.

The ability of LRFN1 to interact with SLAM-2 and other synaptic proteins suggests that it may be a useful biomarker or drug target for SLAM-2-related disorders. Further studies are needed to determine the role of LRFN1 in SLAM-2-related disorders. and to develop effective treatments.

Protein Name: Leucine Rich Repeat And Fibronectin Type III Domain Containing 1

Functions: Promotes neurite outgrowth in hippocampal neurons. Involved in the regulation and maintenance of excitatory synapses. Induces the clustering of excitatory postsynaptic proteins, including DLG4, DLGAP1, GRIA1 and GRIN1 (By similarity)

The "LRFN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRFN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets